دورية أكاديمية
First detection of a Mycobacterium tuberculosis XDR clinical isolate harbouring an RpoB I491F mutation in a Ukrainian patient treated in Germany, October 2023.
| العنوان: | First detection of a Mycobacterium tuberculosis XDR clinical isolate harbouring an RpoB I491F mutation in a Ukrainian patient treated in Germany, October 2023. |
|---|---|
| المؤلفون: | Friesen I; Research Center Borstel, Leibniz Lung Center, Supranational and National Reference Center for Mycobacteria, Borstel, Germany., Dreyer V; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany.; Research Center Borstel, Leibniz Lung Center, Molecular and Experimental Mycobacteriology, Borstel, Germany., Klingmüller A; Department I of Internal Medicine, Division of Infectious Diseases, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Zuber S; Department I of Internal Medicine, Division of Infectious Diseases, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Hoffmann AM; Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Medical Faculty and University Hospital of Cologne, Cologne, Germany., Suárez I; Department I of Internal Medicine, Division of Infectious Diseases, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Schütz B; Klinikum Dorsten, St. Elisabeth-Krankenhaus, Dorsten, Germany., Preßel T; Eurofins MVZ Medizinisches Labor Gelsenkirchen GmbH, Eurofins GeLaMed, Gelsenkirchen, Germany., Andres S; Research Center Borstel, Leibniz Lung Center, Supranational and National Reference Center for Mycobacteria, Borstel, Germany., Niemann S; These authors contributed equally to this work and share last authorship.; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany.; Research Center Borstel, Leibniz Lung Center, Molecular and Experimental Mycobacteriology, Borstel, Germany., Rybniker J; These authors contributed equally to this work and share last authorship.; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.; Department I of Internal Medicine, Division of Infectious Diseases, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany. |
| المصدر: | Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2024 Jul; Vol. 29 (28). |
| نوع المنشور: | Journal Article; Case Reports |
| اللغة: | English |
| بيانات الدورية: | Publisher: European Centre for Disease Prevention and Control (ECDC) Country of Publication: Sweden NLM ID: 100887452 Publication Model: Print Cited Medium: Internet ISSN: 1560-7917 (Electronic) Linking ISSN: 1025496X NLM ISO Abbreviation: Euro Surveill Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Stockholm, Sweden : European Centre for Disease Prevention and Control (ECDC) Original Publication: Saint-Maurice : Hôpital national de Saint-Maurice |
| مواضيع طبية MeSH: | Antitubercular Agents*/therapeutic use , Bacterial Proteins*/genetics , DNA-Directed RNA Polymerases*/genetics , Extensively Drug-Resistant Tuberculosis*/diagnosis , Extensively Drug-Resistant Tuberculosis*/drug therapy , Extensively Drug-Resistant Tuberculosis*/microbiology , Mutation* , Mycobacterium tuberculosis*/genetics , Mycobacterium tuberculosis*/isolation & purification , Mycobacterium tuberculosis*/drug effects , Rifampin*/therapeutic use, Adult ; Humans ; Germany ; Microbial Sensitivity Tests ; Ukraine ; Female |
| مستخلص: | This report documents the case of a Ukrainian patient infected with an extensively drug-resistant (XDR) lineage 2 Mycobacterium tuberculosis strain harbouring the rifampicin resistance mutation RpoB I491F. This mutation is not detected by routine molecular WHO-recommended rapid diagnostics, complicating the detection and treatment of these strains. The occurrence of such mutations underscores the need for enhanced diagnostic techniques and tailored treatment regimens, especially in eastern Europe where lineage 2 strains and XDR-tuberculosis are prevalent. |
| References: | N Engl J Med. 2015 Mar 19;372(12):1181-2. (PMID: 25785984) Antimicrob Agents Chemother. 2021 Jan 20;65(2):. (PMID: 33229425) Genome Med. 2020 Nov 25;12(1):104. (PMID: 33239092) Am J Respir Crit Care Med. 2023 Apr 1;207(7):929-935. (PMID: 36455068) Lancet Infect Dis. 2024 Mar;24(3):297-307. (PMID: 37956677) Lancet Infect Dis. 2018 Dec;18(12):1350-1359. (PMID: 30342828) Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0092522. (PMID: 36342155) Emerg Infect Dis. 2023 Nov;29(11):2403-2406. (PMID: 37877680) J Clin Microbiol. 2021 Mar 19;59(4):. (PMID: 33568463) Lancet Microbe. 2023 May;4(5):e358-e368. (PMID: 37003285) |
| فهرسة مساهمة: | Keywords: GeneXpert; I491F; MDR-TB; Rifampicin; Ukraine; XDR-TB |
| المشرفين على المادة: | 0 (Antitubercular Agents) 0 (Bacterial Proteins) EC 2.7.7.6 (DNA-Directed RNA Polymerases) VJT6J7R4TR (Rifampin) 0 (rpoB protein, Mycobacterium tuberculosis) |
| تواريخ الأحداث: | Date Created: 20240712 Date Completed: 20240712 Latest Revision: 20240718 |
| رمز التحديث: | 20240718 |
| مُعرف محوري في PubMed: | PMC11241856 |
| DOI: | 10.2807/1560-7917.ES.2024.29.28.2400420 |
| PMID: | 38994601 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1560-7917 |
|---|---|
| DOI: | 10.2807/1560-7917.ES.2024.29.28.2400420 |